紫杉醇脂质体与多西紫杉醇对乳腺癌疗效及安全性临床观察  

Efficacy and safety analysis of paclitaxel liposome and docetaxel for neoadjuvant chemotherapy of breast cancer

作　　者：陈涵[1] 王娟[2] 张静[2] 

机构地区：[1]甘肃省康复中心医院药械科,甘肃兰州730000 [2]甘肃省肿瘤医院乳腺科,甘肃兰州730050

出　　处：《临床荟萃》2016年第11期1206-1208,共3页Clinical Focus

摘　　要：目的对比乳腺癌的新辅助化疗方案中紫杉醇脂质体与多西紫杉醇治疗效果和安全性的差异。方法对接受新辅助化疗后手术的乳腺癌174例患者的临床资料进行回顾性分析,根据患者自愿选择用药分为观察组（接受紫杉醇脂质体治疗）和对照组（接受多西紫杉醇治疗）,每组各87例,同时两组均给予环磷酰胺及表阿霉素的联合新辅助化疗方案,1个化疗周期为21天,共进行6个化疗周期,结束后过3周再给予手术切除,对两组的治疗效果及不良反应等进行统计分析。结果观察组的病理完全缓解率为10.3%（9/87）,客观缓解率分别为80.5%（70/87）,疾病控制率为95.4%（83/87）,对照组分别为9.2%（8/87）、79.3%（69/87）、93.1%（81/87）,两组比较差异均无统计学意义（P〉0.05）。观察组的白细胞减少（Ⅲ~Ⅳ级）、中性粒细胞减少（Ⅲ~Ⅳ级）、过敏反应、体液潴留、皮肤指甲毒性反应及口腔黏膜炎等的发生率均较对照组显著降低,差异均有统计学意义（均P〈0.05）。结论紫杉醇脂质体对于乳腺癌新辅助化疗的疗效与多西紫杉醇相近,但其化疗的不良反应发生率较低且程度轻,安全性要更高。Objective To analyze the efficacy and safety of paclitaxel liposomal and docetaxel for the neoadjuvant chemotherapy of breast cancer.Methods The clinical data of 174 operable patients with breast cancer who received the neoadjuvant chemotherapy were analyzed.According to the treatment regimens,all patients were divided into the group of paclitaxel liposome（n =87）and group of docetaxel（n =87）.All the patients received a combination therapy with epirubicin and cyclophosphamide,neoadjuvant chemotherapy for 6cycles with 21 days as a course.Surgery was carried out three weeks after the end of chemotherapy,and the chemotherapy efficacy and adverse reaction of two groups were evaluated.Results Pathological complete remission in paclitaxel liposome group and docetaxel group was 10.3%（9/87）and 9.2%（8/87）,respectively;the objective response rate was 80.5%（70/87）and79.3%（69/87）,respectively;and the disease control rate was 95.4%（83/87）and 93.1%（81/87）,respectively;there was no significant difference in therapy efficacy between two groups（P〉0.05）.Safety analysis indicated that all the occurrence rates of skin and nail toxic reaction,body fluid retention,oral mucositis,allergic reaction（such as facial blushing chest distress,palpitation and dyspnea）,gradeⅢ-Ⅳleukopenia and neutropenia in paclitaxel liposome group were significantly lower than those of docetaxel group（P〈0.05）.Conclusion Compared with docetaxel,paclitaxel liposome has the same anti-tumor efficacy with fewer and milder adverse reactions and a higher safety in the neoadjuvant chemotherapy for breast cancer.

关 键 词：乳腺肿瘤 药物疗法 联合 治疗结果 紫杉醇脂质体 多西紫杉醇 

分 类 号：R737.9[医药卫生—肿瘤]